A systematic review 1 including 35 studies (primary and secondary prevention with a total of 77,079 subjects was abstracted in DARE.
Cardiovascular mortality was reduced by 13-14% for every 10% reduction in serum cholesterol.
Non-cardiovascular mortality: Fibrate use resulted in a 30% increase in risk (p=0.01). Hormone use was also associated with an increased risk (55% increase, p<0.05).
Total mortality: For every 10% reduction in serum cholesterol, mortality risk was reduced by 8-10%. However, fibrate use was associated with increased total mortality for all trials (17% increase, p=0.02). Hormones were not used in the primary prevention trials included in this analysis, but in all other sets of trials hormone use was associated with increased mortality (32-33% increase, p=0.01).
Primary/Secondary Keywords